19 November 2020 in Blood
ILIsabelle Lamrissi-Garcia
+7
Congenital erythropoietic porphyria (CEP) is an inborn error of heme synthesis resulting from uroporphyrinogen III synthase (UROS) deficiency and the accumulation of non-physiological porphyrin isomer I metabolites. Clinical features are heterogeneous among CEP patients but usually combine skin photosensitivity and chronic hemolytic anemia, whose severity is related to porphyrin overload. Therapeutic options are essentially symptomatic and unsatisfactory. One promising strategy to treat CEP is to reduce the erythroid production of porphyrins through substrate reduction therapy by inhibiting 5-aminolevulinate synthase 2 (ALAS2), the first and rate-limiting enzyme in the heme biosynthetic pathway. We efficiently reduced porphyrin accumulation after RNAi-mediated downregulation of ALAS2 in human erythroid cellular models of CEP disease. Taking advantage of the physiological iron-dependent post-transcriptional regulation of ALAS2, we evaluated whether iron chelation with deferiprone could decrease ALAS2 expression and subsequent porphyrin production in vitro and in vivo in a CEP murine model. Treatment of UROS-deficient erythroid cell lines and peripheral blood CD34+-derived erythroid cultures from a CEP patient with deferiprone inhibited iron-dependent protein ALAS2 and IRP2 expression and reduced porphyrin production. Furthermore, porphyrin accumulation progressively decreased in red blood cells and urine, and skin photosensitivity in CEP mice treated with deferiprone (1 or 3 mg/ml in drinking water) for 26 weeks was reversed. Hemolysis and iron overload improved upon iron chelation with a full correction of anemia in CEP mice treated at the highest dose of deferiprone. Our findings highlight in both mouse and human models, the therapeutic potential of iron restriction to modulate the phenotype in CEP.
24 July 2025 in The French Journal of Urology
Urolithiasis is a frequent disease whose prevalence is increasing worldwide. The epidemiological study of urinary stone composition allows to understand the lithogenic processes and makes it possible to improve individual management and orienting public health policies to prevent stone disease. We retrospectively report a series of 6825 urinary stones collected in single university hospital of southwest France between 1999 and 2022. Stone composition was determined by infrared spectroscopy and data were analyzed according to period, age, sex and anatomical location. Our results indicated an average age of 49.5years and a male/female sex ratio of 1.99 which tended to decrease over time. In adults, calcium oxalate is the predominant compound, and urolithiasis was preferentially located in the upper urinary tract. Uric acid is more common in bladder stones from men after 50years. Calcium phosphates (especially carbapatite) and struvite were the main constituents of bladder stones from young women aged 20 to 30years, pointing particularly to an infectious process. Drug-induced stones are uncommon, and essentially composed of anti-infective drugs. In children, urolithiasis predominated in the kidney and young boys aged 6 to 10years were mostly affected with urinary stones formed mainly of carbapatite, whereas weddellite was the main compound identified in girls. Our data highlight the composition of urinary stones according to age, gender and anatomic localization over a large two decades period. These results complete epidemiological data previously published in large-scale national studies in France and across the world.